An Open-Label Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer
Latest Information Update: 28 Jul 2020
Price :
$35 *
At a glance
- Drugs Rovalpituzumab tesirine (Primary) ; Dexamethasone
- Indications Small cell lung cancer
- Focus Adverse reactions
- Sponsors AbbVie
- 04 Jun 2019 Results assessing asfety and efficacy of rovalpituzumab in Japanese patients with small cell lung cancer, presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 24 Aug 2018 Status changed from active, no longer recruiting to completed.
- 29 Apr 2018 Planned End Date changed from 25 Mar 2020 to 10 Jun 2019.